Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285349 | PMC |
| http://dx.doi.org/10.1111/dth.15332 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy, drug survival, safety and metabolic parameters of ixekizumab in patients with moderate-to-severe psoriasis in China: A two-year real-world study.
Int Immunopharmacol
December 2024
Department of Dermatology, Peking University People's Hospital, Beijing 100044, China. Electronic address:
Article Synopsis
- A two-year retrospective study involving 258 patients evaluated the long-term efficacy and safety of ixekizumab for treating difficult psoriasis.
- At one year, significant improvements were noted, with 92% of patients reaching PASI 75 and sustained efficacy at two years.
- Common side effects included local injection reactions and allergies, but there were no major concerns regarding latent infections or metabolic issues.
A 3-Year Multicentric Study on Switching from Ustekinumab to Guselkumab in Partial Responders with Psoriasis-IL PSO (Italian Landscape Psoriasis).
Dermatol Ther (Heidelb)
November 2024
Dermatology Unit, IRCCS Humanitas Research Hospital, Via Alessandro Manzoni, 56, Rozzano, Milan, Italy.
Introduction: Guselkumab, a human monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), has shown efficacy in psoriasis and psoriatic arthritis. However, long-term real-world data on its effectiveness in patients with inadequate response to ustekinumab are limited. This study investigates guselkumab's long-term effectiveness and safety in patients with psoriasis with partial response to ustekinumab.
View Article and Find Full Text PDFEfficacy of Ixekizumab in Chinese Patients with Moderate-to-Severe Psoriasis and Special Body Area Involvement: Sub-analysis of a Randomized, Double-Blind, Multicenter Phase 3 Study.
Adv Ther
September 2024
Department of Dermatology, School of Medicine, Rui Jin Hospital, Shanghai Jiao Tong University, 197, Rui Jin Er Road, Shanghai, 200025, China.
Article Synopsis
- The study examined the effectiveness of ixekizumab (IXE) in treating moderate-to-severe psoriasis with special body area involvement (fingernails, scalp, palms) among Chinese patients.
- A post-hoc analysis of a phase 3 trial showed that patients receiving IXE had significantly better improvements in psoriasis symptoms compared to those on placebo, especially noted in scores for nail and scalp severity.
- By Week 60, patients treated with IXE maintained significant improvement in symptom severity, demonstrating ixekizumab's rapid and sustained action against psoriasis.
Article Synopsis
- * Data from a 5-year trial (UNCOVER-3) shows that most patients, regardless of whether they had initial issues in these challenging areas, achieved similar levels of clear skin and overall improvement.
- * A notable finding is that patients without nail involvement had a significant advantage in overall percentage improvement, but overall efficacy was largely comparable across both groups.
Blood-Count-Derived Inflammatory Markers as Predictors of Response to Biologics and Small-Molecule Inhibitors in Psoriasis: A Multicenter Study.
J Clin Med
July 2024
Agrippa Ionescu Emergency Clinical Hospital, 011773 Bucharest, Romania.
: Psoriasis is an immune-mediated chronic disorder associated with various comorbidities. Even though biologics and small-molecule inhibitors are the mainstay treatment for moderate-to-severe psoriasis, there is no current consensus regarding which agent should be used for a specific type of patient. This paper aims to test the reliability of blood-count-derived inflammatory markers in assessing treatment response to biologics and small-molecule inhibitors in psoriasis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!